EC Pulmonology and Respiratory Medicine

The discovery and use of antibiotics is rightfully considered one of the greatest discoveries in medicine of the 20^th century, which allowed saving millions of lives. However, it was initially known that this direction of treatment could not have a long-term, much less permanent effect, quickly accompanied by side effects. Unfortunately, medicine has long concentrated its attention and sought to support only the therapeutic activity of these drugs, without paying due attention to their side effects. At present, when the accumulated consequences of antibiotics have become completely obvious and serious manifestations, it turns out that there are no scientifically sound and hopeful and trustworthy plans to get out of the situation. Antibiotics still occupy a key place in the treatment of diseases, even despite the inadequacy of pathogens for their purpose. But the criticality of the situation and the need for its urgent analysis lies in the fact that the main prospect on the agenda today is the development of new generations of antimicrobial drugs at the molecular, nanotechnological and genetic levels. The likelihood of a further continuation of a trend that has already led to global consequences could have even more dire results.

 Keywords: Acute Pneumonia; Etiology; Pathogenesis; Antibiotics; Side Effects; Disease Concept; Misconceptions

1. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin”. Reviews of Infectious Diseases 4 (1988): 677-678.
2. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 3 (1942): 386-389.
3. Fleming A. "The Nobel Prize in Physiology or Medicine 1945 - Penicillin: Nobel Lecture". NobelPrize.org. (1945).
4. World Health Organization. The top 10 causes of death (2020).
5. Gram C. "Über die isolierte Färbung der Schizomyceten in Schnitt- und Trocken-präparaten". Fortschritte der Medizin 6 (1884): 185-189.
6. “Scientific American”. Munn & Company (1887): 196.
7. Plotkin S., et al. “Vaccines”. Elsevier - Saunders (2012): 542.
8. Avery OT., et al. “Acute lobar pneumonia: prevention and serum treatment”. Monographs of the Rockefeller Institute for Medical Research. Rockefeller Institute for Medical Research, New York (1917).
9. Cole RI. Acute pulmonary infections. De La Mar Lectures. Williams & Wilkins, Baltimore (1927-1928).
10. Sutliff WD and Finland M. “The significance of the newly classified types of pneumococci in disease: types IV to XX inclusive”. Journal of the American Medical Association17 (1933): 1289-1295.
11. Heffron R. “Pneumonia, with special reference to pneumococcus lobar pneumonia”. Cambridge: Harvard University Press (1939).
12. Small JT. “A short history of the pneumococcus with special reference to lobar pneumonia”. Edinburgh Medical Journal 3 (1948): 129-141.
13. Gadsby NJ and Musher DM. “The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures”. Clinical Microbiology Reviews 4 (2022): e00015-22.
14. Lowy FD. “Antimicrobial resistance: the example of Staphylococcus aureus”. Journal of Clinical Investigation 9 (2003): 1265-1273.
15. Walker SR. “Trends and Changes in Drug Research and Development”. Springer Science & Business Media (2012): 109.
16. "MRSA History Timeline: The First Half-Century, 1959-2009". The University of Chicago Medical Center (2010).
17. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
18. "Normal Hemodynamic Parameters - Adult". Edwards Lifesciences LLC (2010).
19. Olivia Vynn. Cardiology secrets. Chapter 41. Adair Edition: 2, illustrated Published by Elsevier Health Sciences (2001): 210.
20. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archiv: European Journal of Physiology 236 (1935): 206-219.
21. Klepikov I. “Acute pneumonia and its purulent and destructive complications in children in the midst of a major industrial centre of Western Siberia”. Dissertation for the degree of Doctor of Medical Science. Leningrad, USSR (1989).
22. I Klepikov. “The Didactics of Acute Lung Inflammation”. Cambridge Scholars Publishing (2022): 320.
23. I Klepikov. “Myths, Legends and Real Facts About Acute Lung Inflammation”. Cambridge Scholars Publishing (2024): 338.
24. GW Waterer., et al. “Septic Shock and Respiratory Failure in Community-acquired Pneumonia Have Different TNF Polymorphism Associations”. American Journal of Respiratory and Critical Care Medicine 7 (2001): 1599-1604.
25. AJ Morgan and AJ Glossop. “Severe community-acquired pneumonia”. BJA Education5 (2016): 167-172.
26. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. Journal of the American Medical Association 8 (2016): 801-810.
27. Wesley H Self., et al. “Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial”. Annals of Emergency Medicine4 (2018): 457-466.
28. National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network., et al. “Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension”. New England Journal of Medicine 6 (2023): 499-510.
29. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Diseases 7 (2019): 1166-1171.
30. Lin CK., et al. “Serum vascular endothelial growth factor affects tissue fluid accumulation and is associated with deteriorating tissue perfusion and oxygenation in severe sepsis: a prospective observational study”. European Journal of Medical Research 1 (2023): 155.
31. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 6 (2023): 615-632.
32. Michael S Niederman and Antoni Torres. “Severe community-acquired pneumonia”. European Respiratory Review166 (2022): 220123.
33. J Johnstone., et al. “Definitions, rates and associated mortality of ICU-acquired pneumonia: A multicenter cohort study”. Journal of Critical Care 75 (2023): 154284.
34. Lakbar I., et al. “Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia”. Scientific Reports 11 (2021): 16497.
35. Lee YH., et al. “Risk factors for mortality in intensive care unit patients with Stenotrophomonas maltophilia pneumonia in South Korea”. Acute and Critical Care 4 (2023): 442-451.
36. C Cillóniz., et al. “Community-acquired pneumonia in outpatients: aetiology and outcomes”. European Respiratory Journal4 (2012): 931-938.
37. Jain S., et al. “CDC EPIC Study Team Community-acquired pneumonia requiring hospitalization among U.S. adults”. New England Journal of Medicine 5 (2015): 415-427.
38. С Castillo. “2020 IDCA/ATS Community-Acquired Pneumonia Guideline: more micro, less macrolide, no HCAP”. 15^th Annual NW Regional Hospital Medicine Conference (2020).
39. JP Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
40. Alex R Schuurman., et al. “The host response in different aetiologies of community-acquired pneumonia”. The Lancet, Discovery Science 81 (2022): 104082.
41. Cheng GS., et al. “Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report”. Annals of the American Thoracic Society 3 (2023): 341-353.
42. Jeremy Hsu. “AI discovers new class of antibiotics to kill resistant bacteria”. New Scientist3472 (2024): 12.
43. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 5 (2008): 408-416.
44. Ruuskanen O., et al. "Viral pneumonia". Lancet9773 (2011): 1264-1275.
45. "Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003". World Health Organization. 21 April 2004. Archived from the original on 19 March 2020. Retrieved 4 February 2020.
46. "MERS situation update, January 2020". World Health Organization. January 2020. Archived from the original on 5 April 2020. Retrieved 28 March 2020.
47. Visseaux B., et al. “Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016”. PLoS One7 (2017): e0180888.
48. Anthony S Fauci. “It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases”. New England Journal of Medicine22 (2022): 2009-2011.
49. COVID-19 pandemic by country and territory. Wikipedia.
50. “Dying in a Leadership Vacuum”. New England Journal of Medicine 383.15 (2020): 1479-1480.
51. Mareiniss DP. “The Emperor Has No Clothes - Medical Journals and Experts Must Stand Up and Condemn the Federal Pandemic Response”. American Journal of Emergency Medicine 45 (2021): 666.
52. COVID-19 pandemic in Sweden. Wikipedia.
53. J Al-Awaida W., et al. "Correlates of SARS-CoV-2 Variants on Deaths, Case Incidence and Case Fatality Ratio among the Continents for the Period of 1 December 2020 to 15 March 2021". Genes (Basel)7 (2021): 1061.
54. LO Gostin and GK Gronvall. “The Origins of Covid-19 — Why It Matters (and Why It Doesn’t)”. New England Journal of Medicine 25 (2023): 2305-2308.
55. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): 808-810.
56. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy 11 (2020): 3386-3390.
57. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases 9 (2020): 2459-2468.
58. Antimicrobial resistance (2021).
59. RE Leiter. Reentry. New England Journal of Medicine27 (2020): e141.
60. JN Rosenquist. “The Stress of Bayesian Medicine — Uncomfortable Uncertainty in the Face of Covid-19”. New England Journal of Medicine 1 (2021): 7-9.
61. Salisbury H. “Helen Salisbury: What might we learn from the covid-19 pandemic?” British Medical Journal 368 (2020): m1087.
62. Oliver D. “David Oliver: Conveyor belt medicine”. British Medical Journal 368 (2020): m162.
63. Palomeque A., et al. “A review of the value of point-of-care testing for community-acquired pneumonia”. Expert Review of Molecular Diagnostics8 (2024): 729-742.
64. MR Millar., et al. “Carriage of antibiotic-resistant bacteria by healthy children”. Journal of Antimicrobial Chemotherapy5 (2001): 605-610.
65. CDC, Saving Lives. Protecting People. Methicillin-resistant Staphylococcus aureus (MRSA). Healthcare Settings. 24/7 (2023).
66. Albrich WC and Harbarth S. “Health-care workers: Source, vector, or victim of MRSA?” Lancet Infectious Diseases 5 (2008): 289-301.
67. Aubry-Damon H., et al. “Antimicrobial resistance in commensal flora of pig farmers”. Emerging Infectious Diseases 5 (2004): 873-879.
68. Graveland H., et al. “Methicillin Resistant Staphylococcus aureus ST398 in Veal Calf Farming: Human MRSA Carriage Related with Animal Antimicrobial Usage and Farm Hygiene”. PLoS ONE6 (2010): e10990.
69. MS Sinha., et al. “Déjà Vu All Over Again - Refusing to Learn the Lessons of Covid-19”. New England Journal of Medicine 6 (2024): 481-483.
70. S Halabi and GL O’Hara. “Preparing for the Next Pandemic - Expanding and Coordinating Global Regulatory Capacity”. New England Journal of Medicine 6 (2024): 484-487.
71. Nuzzo JB and Ledesma JR. “Why did the best prepared country in the world fare so poorly during COVID?” Journal of Economic Perspectives4 (2023): 3-22.
72. Z Wu and JM McGoogan. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. Journal of the American Medical Association 13 (2020): 1239-1242.
73. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology 5 (2021): 2694-2704.
74. Alene M., et al. “Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis”. PLoS One3 (2021): e0249090.
75. “Lessons for a Pandemic (Audio Interview: H. Fineberg and E. Rubin)”. New England Journal of Medicine 388 (2023): e67.
76. D Goldmann., et al. “Preventing and Controlling Global Antimicrobial Resistance - Implementing a Whole-System Approach”. New England Journal of Medicine 8 (2024): 681-685.